The TARDIS trial is testing the safety, tolerability and effectiveness of an intensive blood thinning therapy involving a combination of three drugs instead of the one or two that are normally prescribed.
The scientists have recruited more than 550 patients with stroke or TIA from across the UK but now hope to expand the trial to include up to 4,200 patients from around the world. They believe that by using three anti-platelet drugs (the combination of aspirin, clopidogrel and dipyridamole) instead of the one or two currently used now, the effects of the stroke and chances of recurrence could be greatly reduced.
Strokes happen when the blood supply to part of the brain is cut off by a blood clot or other blockage. Around 150,000 people have a stroke in the UK every year. Stroke patients occupy a fifth of acute hospital beds and a quarter of long-term beds. For about a third of the stroke victims the attack proves fatal and many more are left severely disabled.
TARDIS stands for Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke. The trial is a randomised, parallel-group controlled experiment in which, within 48 hours of a stroke or TIA, half the patients recruited are given the 3-drug combination for one month. The other half receives the existing guideline antiplatelet therapy. Both groups are monitored for 90 days for frequency and severity of recurrent stroke by observers who do not know which treatment the patient has been on.
The major risk of taking an extra antiplatelet drug is the possibility of causing extra bleeding, such as bruising on the skin, into the gut or bleeding into the brain. But the scientists believe the potential benefit of a reduced chance of having another stroke will outweigh the risk of further bleeding.
Chief investigator, Professor Philip Bath from the University’s School of Clinical Sciences said: “We believe this trial will be hugely significant in finding a better treatment for stroke and TIA to minimise the effects and the risk of recurrence in stroke patients. We are going to be able to compare the frequency and severity of recurrent cerebrovascular events in both sets of patients; data which will be invaluable in stroke medicine worldwide.”
The initial UK phase of the TARDIS trial has been funded by the British Heart Foundation through the University’s Division of Stroke Medicine. Now the researchers are seeking funding to expand the trial to include 4,200 new patients from across the world over the next five years.
For up to the minute media alerts, follow us on Twitter at www.twitter.com/UoNPressOffice
Notes to editors: The University of Nottingham, described by The Sunday Times University Guide 2011 as ‘the embodiment of the modern international university’, has award-winning campuses in the United Kingdom, China and Malaysia. It is ranked in the UK’s Top 10 and the World’s Top 75 universities by the Shanghai Jiao Tong (SJTU) and the QS World University Rankings. It was named ‘Europe’s greenest university’ in the UI GreenMetric World University Ranking, a league table of the world’s most environmentally-friendly higher education institutions, which ranked Nottingham second in the world overall.
The University is committed to providing a truly international education for its 40,000 students, producing world-leading research and benefiting the communities around its campuses in the UK and Asia. Impact: The Nottingham Campaign, its biggest ever fund-raising campaign, will deliver the University’s vision to change lives, tackle global issues and shape the future. For more details, visit: www.nottingham.ac.uk/impactcampaign
More than 90 per cent of research at The University of Nottingham is of international quality, according to the most recent Research Assessment Exercise, with almost 60 per cent of all research defined as ‘world-leading’ or ‘internationally excellent’. Research Fortnight analysis of RAE 2008 ranked the University 7th in the UK by research power. The University’s vision is to be recognised around the world for its signature contributions, especially in global food security, energy & sustainability, and health.
More news from the University at:
More information from: Sally Utton, TARDIS Trial Manager on +44 (0)115 823 0287 [email protected]
Emma Rayner – Media Relations Manager
Email: [email protected] Phone: +44 (0)115 951 5793 Location: King’s Meadow Campus